Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).
Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.
« Back to videos